Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | QDPR | P09417 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758301 | 0.89 | HTR6 (0.44) | HTR6HTR2CHTR2AHTR7SIGMAR1 | |
| SCHEMBL7867297 | 0.83 | SIGMAR1 (0.51) | HTR6HTR2CHTR2AHTR7SIGMAR1 | |
| SCHEMBL4359750 | 0.81 | SIGMAR1 (0.50) | HTR2CSIGMAR1DRD2QDPR | |
| Hydrochloric Acid SCHEMBL8321976 | 0.79 | HTR2C (0.51) | HTR2CSIGMAR1DRD2QDPR | |
| Oxalic Acid SCHEMBL7865026 | 0.77 | SIGMAR1 (0.44) | HTR6HTR2CHTR2AHTR7SIGMAR1 | |
| SCHEMBL7870752 | 0.75 | QDPR (0.42) | HTR6HTR2CHTR7QDPRCDK9 | |
| SCHEMBL7864911 | 0.74 | SIGMAR1 (0.51) | HTR6HTR2CHTR2AHTR7SIGMAR1 | |
| SCHEMBL5760127 | 0.74 | HTR2C (0.43) | HTR6HTR2CHTR2AHTR7SIGMAR1 | |
| SCHEMBL6312184 | 0.73 | QDPR (0.55) | HTR6HTR2CHTR2AHTR7SIGMAR1 | |
| SCHEMBL6312469 | 0.71 | HTR6 (0.49) | HTR6HTR2CHTR2AHTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | IDO1, TPH1, IDO2 | HTR6 10/4885HTR2C 13/4885HTR2A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.